Biography

• KleanthisXanthopoulos
  Kleanthis G. Xanthopoulos, Ph.D.
  

  Director
  
  Kleanthis G. Xanthopoulos, Ph.D. has been a director since December 2011. He has been a member of our Compensation, Corporate Governance/Nominating and Finance Committees since 2011. Dr. Xanthopoulos has proven leadership and extensive business and corporate development experience in the pharmaceutical industry.
  
  He is the President and Chief Executive Officer of Regulus Therapeutics Inc. (“Regulus”). Prior to joining Regulus in 2007, Dr. Xanthopoulos was the Managing Director of Enterprise Partners Venture Capital. He co-founded Anadys Pharmaceuticals, served as President and Chief Executive Officer from 2000 to 2006, and remained a Director until its acquisition by Roche in 2011. Before that, Dr. Xanthopoulos was Vice President at Aurora Biosciences (acquired by Vertex Pharmaceuticals) from 1997 to 2000, and Section Head of the National Human Genome Research Institute from 1995 to 1997. Previously, he was an Associate Professor at the Karolinska Institute, Stockholm, Sweden, after completing a Postdoctoral Research Fellow at The Rockefeller University, New York.
  
  An Onassis Foundation Scholar, Dr. Xanthopoulos received his B.Sc. in Biology with honors from Aristotle University of Thessaloniki, Greece, and his M.Sc. degree in Microbiology and Ph.D. degree in Molecular Biology from the University of Stockholm, Sweden. Dr. Xanthopoulos is a member of the board of directors of the Biotechnology Industry Organization (BIO), Sente Inc., and a member of the executive board of BIOCOM, Southern California's life science industry association.